Preterm birth is the primary driver of perinatal morbidity and mortality affecting approximately 11% of all newborns in the United States.1 Of the 4 million neonatal deaths that occur annually around the world, more than a quarter are the result of preterm birth.2 A short cervix by ultrasound has been noted to be one of the strongest predictors of subsequent preterm birth and investigators have focused efforts in finding a treatment for women with a short cervix that will reduce the risk of preterm delivery. Although vaginal progesterone and cerclage have been shown to reduce the risk, results have not been uniformly positive, and a low-cost, simple and effective method would be of great value, especially globally. The cervical pessary is such a treatment. This randomized trial will evaluate whether a cervical pessary can reduce the risk of preterm birth before 37 weeks in women with a short cervix.

You may be eligible for this study if you meet the following criteria:

• Conditions: ['Short Cervix', 'Preterm Delivery']
• Age: 99 years or below
• Gender: All